Antibodies to watch in 2024
S Crescioli, H Kaplon, A Chenoweth, L Wang… - MAbs, 2024 - Taylor & Francis
ABSTRACT The 'Antibodies to Watch'article series provides an annual summary of
commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical …
commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical …
Hereditary angioedema: a review of the current and evolving treatment landscape
SD Betschel, A Banerji, PJ Busse, DM Cohn… - The Journal of Allergy …, 2023 - Elsevier
Hereditary angioedema (HAE) is a rare disease characterized by sudden and often
unprovoked episodes of swelling that can be potentially life-threatening when it involves the …
unprovoked episodes of swelling that can be potentially life-threatening when it involves the …
Could it be hereditary angioedema?—Perspectives from different medical specialties
M Magerl, A Sala‐Cunill… - Clinical and …, 2023 - Wiley Online Library
Hereditary angioedema (HAE) is a rare autosomal dominant disease, with patients often
suffering with associated symptoms for many years before receiving a correct diagnosis. The …
suffering with associated symptoms for many years before receiving a correct diagnosis. The …
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks
MA Riedl, H Farkas, E Aygören-Pürsün… - … England Journal of …, 2024 - Mass Medical Soc
Background Approved on-demand treatments for hereditary angioedema attacks need to be
administered parenterally, a route of administration that is associated with delays in …
administered parenterally, a route of administration that is associated with delays in …
Normalization of C1 Inhibitor in a Patient with Hereditary Angioedema
Hereditary angioedema is a potentially life-threatening autosomal dominant condition,
causing attacks of angioedema due to failure to regulate bradykinin. Nearly all cases of …
causing attacks of angioedema due to failure to regulate bradykinin. Nearly all cases of …
[HTML][HTML] Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation
AC Clermont, N Murugesan, HJ Edwards… - Frontiers in …, 2023 - frontiersin.org
Background: The kallikrein kinin system (KKS) is an established pharmacological target for
the treatment and prevention of attacks in hereditary angioedema (HAE). Proteolytic …
the treatment and prevention of attacks in hereditary angioedema (HAE). Proteolytic …
Cold urticaria syndromes: diagnosis and management
VL Diaz, KB Gribbons, K Yazdi-Nejad… - The Journal of Allergy …, 2023 - Elsevier
Cold urticaria is a chronic condition causing episodic symptoms of cold-induced wheals or
angioedema in response to direct or indirect exposure to cold temperatures. Whereas …
angioedema in response to direct or indirect exposure to cold temperatures. Whereas …
Increased thromboinflammatory load in hereditary angioedema
OR Gramstad, C Schjalm, TE Mollnes… - Clinical and …, 2023 - academic.oup.com
Abstract C1 inhibitor (C1Inh) is a serine protease inhibitor involved in the kallikrein-kinin
system, the complement system, the coagulation system, and the fibrinolytic system. In …
system, the complement system, the coagulation system, and the fibrinolytic system. In …
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies
H Farkas, Z Balla - Expert opinion on investigational drugs, 2024 - Taylor & Francis
Introduction Hereditary angioedema (HAE) is a rare genetic disorder characterized by
recurrent edema and predominantly caused by the dysregulation of the kinin-kallikrein …
recurrent edema and predominantly caused by the dysregulation of the kinin-kallikrein …
Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema
MA Riedl, L Bordone, A Revenko, KB Newman… - The Journal of Allergy …, 2023 - Elsevier
Hereditary angioedema (HAE) is typically caused by a deficiency of the protease inhibitor
C1 inhibitor (C1INH). The absence of C1INH activity on plasma kallikrein and factor XIIa …
C1 inhibitor (C1INH). The absence of C1INH activity on plasma kallikrein and factor XIIa …